Evidence map›Paper›PMID 32526275›Full record

Observational studyClinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases2020

Risk factors for disease progression in patients with mild to moderate coronavirus disease 2019-a multi-centre observational study.

Y Cen, X Chen, Y Shen, X-H Zhang, Y Lei, C Xu, W-R Jiang, H-T Xu, Y Chen, J Zhu and 2 more

Open access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers, 16 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 16 pooled it
4.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 16 syntheses or guidelines pooled it, 173 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Meta-analysis of cardiac markers for predictive factors on severity and mortality of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021
    Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Trial
  18. Trial
  19. Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Y CenDepartment of Orthopedics, Daping Hospital, Army Medical University, Chongqing, China; Department of Infectious Disease, Huoshenshan Hospital, Wuhan, China.
X ChenDepartment of Anaesthesiology, Daping Hospital, Army Medical University, Chongqing, China; Department of Critical Care Medicine, Huoshenshan Hospital, Wuhan, China.
Y ShenDepartment of Respiratory Disease, Daping Hospital, Army Medical University, Chongqing, China.
X-H ZhangDepartment of Infectious Disease, Huoshenshan Hospital, Wuhan, China; Department of General Surgery, Daping Hospital, Army Medical University, Chongqing, China.
Y LeiDepartment of Infectious Disease, Huoshenshan Hospital, Wuhan, China; Department of Anaesthesiology, Daping Hospital, Army Medical University, Chongqing, China.
C XuDepartment of Oncology, General Hospital of the Central Theatre Command of the People's Liberation Army, Wuhan, China.
W-R JiangDepartment of Critical Care Medicine, Huoshenshan Hospital, Wuhan, China; Department of Respiratory Disease, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
H-T XuDepartment of Critical Care Medicine, Huoshenshan Hospital, Wuhan, China; Department of Anaesthesiology, Changzheng Hospital, Second Military Medical University, Shanghai, China.
Y ChenDepartment of Infectious Disease, Huoshenshan Hospital, Wuhan, China; Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical University, Chongqing, China.
J ZhuDepartment of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical University, Chongqing, China.
L-L ZhangDepartment of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical University, Chongqing, China. Electronic address: zll19731220@126.com.
Y-H LiuDepartment of Critical Care Medicine, Huoshenshan Hospital, Wuhan, China; Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital, Army Medical University, Chongqing, China. Electronic address: liuyuhui07-8909@163.com.
Army Medical University · CNCentral Hospital of Wuhan · CNSecond Military Medical University · CNXijing Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSince December 2019, the novel coronavirus disease 2019 (COVID-19) that emerged in Wuhan city has spread rapidly around the world. The risk for poor outcome dramatically increases once a patient progresses to the severe or critical stage. The present study aims to investigate the risk factors for disease progression in individuals with mild to moderate COVID-19.

methodsWe conducted a cohort study that included 1007 individuals with mild to moderate COVID-19 from three hospitals in Wuhan. Clinical characteristics and baseline laboratory findings were collected. Patients were followed up for 28 days for observation of disease progression. The end point was the progression to a more severe disease stage.

resultsDuring a follow up of 28 days, 720 patients (71.50%) had recovered or were symptomatically stable, 222 patients (22.05%) had progressed to severe disease, 22 patients (2.18%) had progressed to the critically ill stage and 43 patients (4.27%) had died. Multivariate Cox proportional hazards models identified that increased age (hazard ratio (HR) 2.56, 95% CI 1.97-3.33), male sex (HR 1.79, 95% CI 1.41-2.28), presence of hypertension (HR 1.44, 95% CI 1.11-1.88), diabetes (HR 1.82, 95% CI 1.35-2.44), chronic obstructive pulmonary disease (HR 2.01, 95% CI 1.38-2.93) and coronary artery disease (HR 1.83, 95% CI 1.26-2.66) were risk factors for disease progression. History of smoking was protective against disease progression (HR 0.56, 95% CI 0.34-0.91). Elevated procalcitonin (HR 1.72, 95% CI 1.02-2.90), urea nitrogen (HR 1.72, 95% CI 1.21-2.43), α-hydroxybutyrate dehydrogenase (HR 3.02, 95% CI 1.26-7.21) and D-dimer (HR 2.01, 95% CI 1.12-3.58) at baseline were also associated with risk for disease progression.

conclusionsThis study identified a panel of risk factors for disease progression in individuals with mild to moderate COVID-19.

Indexed as

Disease ProgressionAdolescentAdultAgedAge FactorsBlood Urea NitrogenChildChild, PreschoolChinaComorbidityCoronary Artery DiseaseCOVID-19Diabetes MellitusFemaleFibrin Fibrinogen Degradation ProductsHumans2-hydroxybutyrate dehydrogenaseFibrin Fibrinogen Degradation Productsfibrin fragment DHydroxybutyrate DehydrogenaseProcalcitoninCo-morbidityCoronavirus disease 2019Disease progressionLaboratory findingsRisk factors

Identifiers

PMID32526275
PMCPMC7280135
OpenAlexW3033884134

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.